| BRO |
Report |
Consolidated Organic Revenue Growth (ex-contingents) |
MISS |
pred ~1.5% vs. cons ~2.6% |
MEDIUM |
| BRO |
Report |
Adjusted Diluted EPS |
BEAT |
pred ~$1.11 vs. cons ~$1.09 |
HIGH |
| BRO |
Report |
Total Revenue |
IN-LINE |
pred ~$1.73B vs. cons ~$1.72B |
HIGH |
| BRO |
Guide |
FY2026 Organic Revenue Growth outlook/commentary |
LOWER |
guide ~3.0% vs. cons ~4.0% (FY2026) |
MEDIUM |
| BRO |
Guide |
FY2026 Adjusted EBITDAC Margin Expansion |
LOWER |
guide ~+20bps vs. cons ~+40bps (FY2026) |
MEDIUM |
| BRO |
Guide |
Accession/Risk Strategies EBITDA Synergy Target |
UNCHANGED |
guide ~$35M vs. cons ~$35M (FY2026, midpoint of $30-40M range reaffirmed) |
MEDIUM |
| BRO |
Guide |
Howden litigation annualized lost revenue trajectory |
LOWER |
guide/actual ~$36M vs. prior-quarter ~$31M (Q2 2026 cumulative, deceleration not yet evident) |
LOW |
| BRO |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
MEDIUM |
| BRO |
Return |
5-day cumulative residual |
-6.5% (FOLLOW-THROUGH) |
Peer read-throughs (MMC/Guy Carpenter Q2 results showing global property cat rate declines accelerating to -16% at midyear from -12% in Q1, with Guy Carpenter posting negative organic growth) confirm the CAT-property pricing headwind BRO flagged is intensifying rather than stabilizing, undercutting management's promised sequential organic-growth improvement into Q2/H2. Even with a modest EPS beat driven by contingents and buybacks, the out-period math means FY26 organic growth and margin-expansion estimates get trimmed post-call as analysts push the 'inflection' further into H2 and haircut confidence in the '180' casualty-book and Accession-synergy offsets, while continued Howden litigation bleed and elevated leverage keep the credibility question (raised by Morgan Stanley's downgrade) alive - producing a grinding downward drift over the week rather than a snap-back. |
MEDIUM |